Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Development of a stem cell therapy for sickle cell disease from ... up to six new CRISPR/Cas9-based treatments that emerge from the collaboration, and CTX001 represents the first treatment to ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

If this happens, it’s usually within the first ... treatment, a new gene would be introduced into cancer cells. This would either cause the cancer cells to die off or prevent them from growing ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

In addition, the CRISPR-based gene modification process is mostly harmless for the targeted cells, reducing the ... where it is approved (including the US and the EU), making it the first credible ...

Several approaches involve using CRISPR-Cas9 technology ... “It’s a multifaceted, complex disease, but a lot of the same cytokines that are used as treatment targets in rheumatoid arthritis ...

The CRISPR-led gene-editing revolution is set to begin next month in its first ever trial ... cancer (NSCLC) whose disease has progressed after previous standard treatment. The CRISPR-Cas9 ...